Method of treatment to inhibit the undesirable activation of the

Details Method of treatment to inhibit the undesirable activation of the Method of treatment to inhibit the undesirable activation of the

1992-04-27

1993-12-07

Wax, Robert A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530350, 530412, 530413, 530415, 530416, C07K 328, A61K 3702

Patent

active

052683630

ABSTRACT:
A purified protein, factor J, which has inhibitory properties which prevent the formation or the dissociation of Cl complex and a method of purification for said protein. The method including the following sequential chromatography steps: anion exchange QAE-"SEPHADEX", heparin-"SEPHAROSE" affinity, "MONO Q" and hydroxylapatite.

REFERENCES:
patent: 4147801 (1979-04-01), Lenhard et al.
patent: 4388232 (1983-06-01), Eibl et al.
patent: 4883784 (1989-11-01), Kaneko
patent: 4915945 (1990-04-01), Pelzer et al.
patent: 5109114 (1992-04-01), Nicholson-Weller
Sofer et al. Nov./Dec. 1983, Bio/Techniques, pp. 198-203.
Cooper, "The Classical Complement Pathway: Activation and Regulation of the First Complement Component" 37 Adv. Immunol 151-216 (1985).
Schumaker et al., "Activation of the First Component of Complement" 5 Ann. Rev. Immunol. 21-42 (1987).
Reid et al., "The Proteologic Activation Systems of Complement" 50 Ann. Rev. Biochem. 433-464 (1981).
Ziccardi, "The Role of Immune Complexes in the Activation of the First Component of Human Complement" 132 J. Immunol. 282-288 (1984).
Ziccardi, "Demonstration of the Interaction of Native C1 with Monomeric Immunoglobulins and C1 Inhibitor" 134 J. Immunol. 2559-2563 (1985).
Silvestri et al., "The C1q Inhibitor in Serum is a Chondroitin 4-Sulfate Proteoglycan" 256 J. Biol. Chem. 7383-7387 (1981).
Ghebrehiwet, "C1q Inhibitor (C1qINH): Functional Properties and Possible Relationship to a Lymphocyte Membrane-Associated Cq1 Precipitin" 126 J. Immunol. 1837-1842 (1981).
Ghebrehiwet, "Purification and Partial Characterization of a C1q Inhibitor from the Membranes of Human Peripheral Blood Lymphocytes" 129 J. Immunol. 151-162 (1982).
Davis, "C1 Inhibitor and Hereditary Angioneurotic Edema" 6 Ann. Rev. Immunol. 595-628 (1988).
Lopez-Trascasa et al., 1989, J. Biol. Chem. 264(27): 16714-16221.
Abstract, Biosis No. 2064952 of Cheung et al. 1986, Biochem Biophys Acta 882(2): 200-209.
Ghebrehiwet et al., 1988, J. Immunol Methods 110: 251-260.

Affiliated with

Also associated with

Rating

Method of treatment to inhibit the undesirable activation of the does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treatment to inhibit the undesirable activation of the, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment to inhibit the undesirable activation of the will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2015807